For adjuvant therapy of human epidermal growth factor receptor 2 (HER2) positive breast cancer, combinations of docetaxel and trastuzumab (and pertuzumab) demonstrate synergistic cytotoxic activity while also being favorable from both safety and efficacy perspectives (Burris, 2001). The gene discussed is ERBB2; the disease is breast carcinoma.